Home › Compare › VYNT vs SBUX

VYNT vs SBUX: Dividend Comparison 2026

VYNT yields 1030.93% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VYNT wins by $24587954.03M in total portfolio value
10 years
VYNT
VYNT
● Live price
1030.93%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24587954.20M
Annual income
$20,648,027,961,236.51
Full VYNT calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — VYNT vs SBUX

📍 VYNT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVYNTSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VYNT + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VYNT pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VYNT
Annual income on $10K today (after 15% tax)
$87,628.87/yr
After 10yr DRIP, annual income (after tax)
$17,550,823,767,051.04/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, VYNT beats the other by $17,550,823,706,585.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VYNT + SBUX for your $10,000?

VYNT: 50%SBUX: 50%
100% SBUX50/50100% VYNT
Portfolio after 10yr
$12293977.18M
Annual income
$10,324,014,016,186.48/yr
Blended yield
83.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

VYNT
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-12.0
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VYNT buys
0
SBUX buys
0
No recent congressional trades found for VYNT or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVYNTSBUX
Forward yield1030.93% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$24587954.20M ✓$167.0K
Annual income after 10y$20,648,027,961,236.51 ✓$71,136.45
Total dividends collected$24288183.04M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: VYNT vs SBUX ($10,000, DRIP)

YearVYNT PortfolioVYNT Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$113,793$103,092.78$11,121$420.68+$102.7K → VYNT
2$1,218,133$1,096,375.21$12,548$648.40+$1.21M → VYNT
3$12,272,114$10,968,711.02$14,440$1,013.98+$12.26M → VYNT
4$116,406,425$103,275,262.74$17,068$1,617.30+$116.39M → VYNT
5$1,040,079,657$915,524,782.99$20,912$2,649.52+$1040.06M → VYNT
6$8,757,858,648$7,644,973,414.41$26,875$4,499.29+$8757.83M → VYNT
7$69,533,084,085$60,162,175,331.66$36,771$8,014.12+$69533.05M → VYNT
8$520,809,783,127$446,409,383,156.47$54,542$15,197.11+$520809.73M → VYNT
9$3,682,174,050,693$3,124,907,582,747.50$89,602$31,242.49+$3682173.96M → VYNT
10$24,587,954,195,479$20,648,027,961,236.51$167,011$71,136.45+$24587954.03M → VYNT

VYNT vs SBUX: Complete Analysis 2026

VYNT — Stock

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Full VYNT Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this VYNT vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VYNT vs SCHDVYNT vs JEPIVYNT vs OVYNT vs KOVYNT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.